SEC Form 4 · accession 0001221590-26-000015
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 5:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2026 | S | 500 | $19.44 | D | 42,915 | D | |
| Common Stock | Jun 5, 2026 | S | 10,000 | $19.41 | D | 32,915 | D | |
| Common Stock | Jun 5, 2026 | P | 6,000 | $19.48 | A | 38,915 | D | |
| Common Stock | Jun 5, 2026 | P | 3,500 | $19.46 | A | 42,415 | D | |
| Common Stock | Jun 5, 2026 | P | 1,000 | $19.27 | A | 43,415 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales by the reporting person reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person at the price of $19.27 per share on June 5, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $155, representing the full amount of the profit realized in connection with the short-swing transaction.
- F2The reporting person sold and reacquired the same aggregate number of shares on June 5, 2026.